{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T17:38:55Z","timestamp":1743097135464,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":31,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071644416"},{"type":"electronic","value":"9781071644423"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4442-3_9","type":"book-chapter","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T13:17:57Z","timestamp":1741007877000},"page":"119-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, Production, and Optimization of Antigen-Specific Recombinant Antitumor Dimeric IgA Antibody"],"prefix":"10.1007","author":[{"given":"Baishali","family":"Tamuli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutik","family":"Ghagare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunjan","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"issue":"13","key":"9_CR1","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI et al (2020) KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med 383(13):1207\u20131217. https:\/\/doi.org\/10.1056\/NEJMoa1917239","journal-title":"N Engl J Med"},{"key":"9_CR2","doi-asserted-by":"crossref","unstructured":"Chaurio RA, Anadon CM, Costich TL, Payne KK, Biswas S, Harro CM et al (2022) TGF-\u03b2-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. 55(1):115\u2013128. e119","DOI":"10.1016\/j.immuni.2021.12.007"},{"key":"9_CR3","doi-asserted-by":"publisher","unstructured":"Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA et al (2021) IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. https:\/\/doi.org\/10.1038\/s41586-020-03144-0","DOI":"10.1038\/s41586-020-03144-0"},{"key":"9_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101419","volume":"49","author":"JR Conejo-Garcia","year":"2020","unstructured":"Conejo-Garcia JR, Biswas S, Chaurio R (2020) Humoral immune responses: unsung heroes of the war on cancer. Semin Immunol 49:101419. https:\/\/doi.org\/10.1016\/j.smim.2020.101419","journal-title":"Semin Immunol"},{"key":"9_CR5","first-page":"101707","volume-title":"Seminars in immunology","author":"JR Conejo-Garcia","year":"2023","unstructured":"Conejo-Garcia JR, Biswas S, Chaurio R, Rodriguez PC (2023) Neglected no more: B cell-mediated anti-tumor immunity. In: Seminars in immunology, vol 65. Elsevier, p 101707"},{"issue":"2","key":"9_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.4049\/jimmunol.1701269","volume":"200","author":"VH Engelhard","year":"2018","unstructured":"Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr (2018) Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity. J Immunol 200(2):432\u2013442. https:\/\/doi.org\/10.4049\/jimmunol.1701269","journal-title":"J Immunol"},{"issue":"5","key":"9_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/0008-5472.Can-21-2376","volume":"82","author":"G Mandal","year":"2022","unstructured":"Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S et al (2022) IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer. Cancer Res 82(5):859\u2013871. https:\/\/doi.org\/10.1158\/0008-5472.Can-21-2376","journal-title":"Cancer Res"},{"key":"9_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1385\/1-59259-076-4:267","volume":"40","author":"J Freysd\u2019ottir","year":"2000","unstructured":"Freysd\u2019ottir J (2000) Production of monoclonal antibodies. Methods Mol Med 40:267\u2013279. https:\/\/doi.org\/10.1385\/1-59259-076-4:267","journal-title":"Methods Mol Med"},{"issue":"23\u201324","key":"9_CR9","first-page":"1573","volume":"100","author":"M Kaartinen","year":"1984","unstructured":"Kaartinen M (1984) The 1984 nobel prize in medicine (Cesar Milstein, George K\u00f6hler, Niels Jerne). Duodecim 100(23\u201324):1573\u20131578","journal-title":"Duodecim"},{"issue":"4","key":"9_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278\u2013287. https:\/\/doi.org\/10.1038\/nrc3236","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"9_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","volume":"4","author":"S Zinn","year":"2023","unstructured":"Zinn S, Vazquez-Lombardi R, Zimmermann C, Sapra P, Jermutus L, Christ D (2023) Advances in antibody-based therapy in oncology. Nat Cancer 4(2):165\u2013180. https:\/\/doi.org\/10.1038\/s43018-023-00516-z","journal-title":"Nat Cancer"},{"issue":"3","key":"9_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1200\/jco.1999.17.3.791","volume":"17","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP et al (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17(3):791\u2013795. https:\/\/doi.org\/10.1200\/jco.1999.17.3.791","journal-title":"J Clin Oncol"},{"issue":"10","key":"9_CR13","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O\u2019Brien S, Valente N et al (2017) Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34(10):2232\u20132273. https:\/\/doi.org\/10.1007\/s12325-017-0612-x","journal-title":"Adv Ther"},{"issue":"3","key":"9_CR14","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC et al (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186(3):1840\u20131848. https:\/\/doi.org\/10.4049\/jimmunol.1003032","journal-title":"J Immunol"},{"issue":"4","key":"9_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/ctrv.2000.0182","volume":"26","author":"J Stebbing","year":"2000","unstructured":"Stebbing J, Copson E, O\u2019Reilly S (2000) Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev 26(4):287\u2013290. https:\/\/doi.org\/10.1053\/ctrv.2000.0182","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 2","key":"9_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000055400","volume":"61","author":"CL Vogel","year":"2001","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al (2001) First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61(Suppl 2):37\u201342. https:\/\/doi.org\/10.1159\/000055400","journal-title":"Oncology"},{"key":"9_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-016-0177-2","volume":"4","author":"S Agrawal","year":"2016","unstructured":"Agrawal S, Feng Y, Roy A, Kollia G, Lestini B (2016) Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 4:72. https:\/\/doi.org\/10.1186\/s40425-016-0177-2","journal-title":"J Immunother Cancer"},{"issue":"2","key":"9_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.seminoncol.2017.06.007","volume":"44","author":"V Prasad","year":"2017","unstructured":"Prasad V, Kaestner V (2017) Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol 44(2):132\u2013135. https:\/\/doi.org\/10.1053\/j.seminoncol.2017.06.007","journal-title":"Semin Oncol"},{"issue":"16","key":"9_CR19","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM (2014) Pembrolizumab: first global approval. Drugs 74(16):1973\u20131981. https:\/\/doi.org\/10.1007\/s40265-014-0314-5","journal-title":"Drugs"},{"key":"9_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","volume":"3","author":"L Khoja","year":"2015","unstructured":"Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM (2015) Pembrolizumab. J Immunother Cancer 3:36. https:\/\/doi.org\/10.1186\/s40425-015-0078-9","journal-title":"J Immunother Cancer"},{"issue":"15 suppl","key":"9_CR21","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/jco.2012.30.15_suppl.2510","volume":"30","author":"SS Tykodi","year":"2012","unstructured":"Tykodi SS, Brahmer JR, Hwu W-J, Chow LQ, Topalian SL, Hwu P et al (2012) PD-1\/PD-L1 pathway as a target for cancer immunotherapy: safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. J Clin Oncol 30(15 suppl):2510\u20132510. https:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.2510","journal-title":"J Clin Oncol"},{"issue":"1","key":"9_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","volume":"65","author":"G Graziani","year":"2012","unstructured":"Graziani G, Tentori L, Navarra P (2012) Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 65(1):9\u201322. https:\/\/doi.org\/10.1016\/j.phrs.2011.09.002","journal-title":"Pharmacol Res"},{"issue":"5","key":"9_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","volume":"37","author":"A Hoos","year":"2010","unstructured":"Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V et al (2010) Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37(5):533\u2013546. https:\/\/doi.org\/10.1053\/j.seminoncol.2010.09.015","journal-title":"Semin Oncol"},{"issue":"9","key":"9_CR24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/bph.13450","volume":"173","author":"S Carvalho","year":"2016","unstructured":"Carvalho S, Levi-Schaffer F, Sela M, Yarden Y (2016) Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR review 18. Br J Pharmacol 173(9):1407\u20131424. https:\/\/doi.org\/10.1111\/bph.13450","journal-title":"Br J Pharmacol"},{"issue":"4","key":"9_CR25","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A et al (2022) Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J Med Chem 65(4):3123\u20133133. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01688","journal-title":"J Med Chem"},{"issue":"25","key":"9_CR26","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW et al (2021) Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med 384(25):2382\u20132393. https:\/\/doi.org\/10.1056\/NEJMoa2105281","journal-title":"N Engl J Med"},{"issue":"19","key":"9_CR27","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/jco.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167\u20133175. https:\/\/doi.org\/10.1200\/jco.2009.26.7609","journal-title":"J Clin Oncol"},{"key":"9_CR28","doi-asserted-by":"publisher","first-page":"1076312","DOI":"10.3389\/fimmu.2022.1076312","volume":"13","author":"RA Strugnell","year":"2022","unstructured":"Strugnell RA (2022) When secretion turns into excretion\u2014the different roles of IgA. Front Immunol 13:1076312. https:\/\/doi.org\/10.3389\/fimmu.2022.1076312","journal-title":"Front Immunol"},{"issue":"11","key":"9_CR29","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.immuni.2023.09.013","volume":"56","author":"S Biswas","year":"2023","unstructured":"Biswas S, Mandal G, Anadon CM, Chaurio RA, Lopez-Bailon LU, Nagy MZ et al (2023) Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. Immunity 56(11):2570\u20132583.e2576. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.013","journal-title":"Immunity"},{"key":"9_CR30","doi-asserted-by":"publisher","unstructured":"Intracellular Oncoproteins Can Be Targeted by Mutation-Specific Dimeric IgA (2024) Cancer Discov 14(1):14. https:\/\/doi.org\/10.1158\/2159-8290.Cd-rw2023-182","DOI":"10.1158\/2159-8290.Cd-rw2023-182"},{"issue":"11","key":"9_CR31","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.immuni.2023.10.014","volume":"56","author":"S Prince","year":"2023","unstructured":"Prince S, Hollm\u00e9n M (2023) Dimeric IgA specifically disables intracellular mutated oncodrivers. Immunity 56(11):2461\u20132463. https:\/\/doi.org\/10.1016\/j.immuni.2023.10.014","journal-title":"Immunity"}],"container-title":["Methods in Molecular Biology","B-Cell Receptor Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4442-3_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T13:18:00Z","timestamp":1741007880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4442-3_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071644416","9781071644423"],"references-count":31,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4442-3_9","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"4 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}